IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9). FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%.
From IOL Chemicals & Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 11 Sept 2026.
Revenue & Sales Performance
- For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9).
- Growth is driven by higher capacity utilization, better product mix, operational efficiencies, and strong demand in domestic and export markets (Page 9).
- For FY28, a similar growth rate of 15% to 20% in top line and 15% to 17% EBITDA margin is targeted, subject to market conditions (Page 9).
- Sustainable growth is supported by a diversified and broad-based product portfolio expanding beyond ibuprofen (Page 7, 13).
- Export contribution is targeted around 25% to 30% of revenue, with potential to move toward 30%+ (Pages 4, 15).
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on revenue
Every concall, every company
Profitability & Margins
See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.
- The company has a 101-acre land parcel for future expansion, with statutory permissions underway.
- Major new projects on this land are not expected to be commissioned within the current fiscal year (FY27); likely FY28 or FY29 growth platforms.
- IOL is actively working on R&D initiatives, with investments in advanced analytical equipment (XRD, LCMS, GCMS) to support product development.
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on capex
Every concall, every company
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- IOL Chemicals and Pharmaceuticals Limited has reasonable visibility into their order book for the coming quarter as of Q1 FY27.
- The company expects sustained demand based on this order book visibility, supporting their confident revenue growth guidance.
- They anticipate revenue growth of around 15% to 20% with EBITDA margins around 14% to 15% for FY27, indicating a healthy order inflow.
- The management did not provide specific quantitative details on the size of the order book but emphasized strong demand in domestic and export markets.
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on order book
Every concall, every company
IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What IOL Chemicals's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key concall takeaways from Beta Drugs Ltd's Q1 FY27…
Arthneeti Pro · Annual
IOL Chemicals & Pharmaceuticals Ltd and 1,500+ more calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were IOL Chemicals & Pharmaceuticals Ltd Q1 FY27 results?
For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9). FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%.
What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?
IOL Chemicals & Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 33.2 with a market cap of ₹5,869 Cr. Investors should review the full earnings analysis for detailed insights.
Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?
IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.
Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.